Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2008
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00268359 (Bevacizumab in Combination With Irinotecan for Malignant Gliomas), which is not on this map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bevacizumab in Combination With Irinotecan for Malignant Gliomas
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.Neuro-oncology · 2015Trial
- Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.BioMed research international · 2014Trial
- Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.Journal of neuro-oncology · 2012Trial
- A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.Neuro-oncology · 2011Trial
- Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.Journal of neuro-oncology · 2011Trial
- Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.Neuro-oncology · 2010Trial
- Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.British journal of cancer · 2009Trial
- Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma: A Nationwide Population-Based Study.Journal of Korean medical science · 2024Article
- Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.Neuro-oncology · 2019Review
- Lower-grade gliomas: the wrong target for bevacizumab.Neuro-oncology · 2018Article
- A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma.Oncotarget · 2018Article
- Article
- Current therapeutic approaches to diffuse grade II and III gliomas.Therapeutic advances in neurological disorders · 2018Article
- Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences.Oncology letters · 2016Article
- GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Article
- Anaplastic astrocytoma.CNS oncology · 2016Review
- Induction of WNT11 by hypoxia and hypoxia-inducible factor-1α regulates cell proliferation, migration and invasion.Scientific reports · 2016Article
- Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?Oncotarget · 2016Review
- Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis.OncoTargets and therapy · 2016Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeAlthough patients with newly diagnosed WHO grade 3 malignant glioma have a more favorable prognosis than those with WHO grade 4 malignant glioma, salvage therapies following recurrence offer essentially palliative benefit. We did a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan for patients with recurrent grade 3 malignant glioma. EXPERIMENTAL
designUpon documentation of adequate safety among an initial cohort of nine patients treated with bevacizumab (10 mg/kg) and irinotecan every 14 days, a second cohort (n=24) was treated with bevacizumab (15 mg/kg) every 3 weeks with irinotecan on days 1, 8, 22, and 29 of each 42-day cycle. For both cohorts, the dose of irinotecan was 340 mg/m(2) for patients on enzyme-inducing antiepileptic drugs (EIAED) and 125 mg/m(2) for patients not on EIAEDs. After each 6-week cycle, patients were evaluated with a physical examination and magnetic resonance imaging.
resultsThe 6-month progression-free survival was 55% (95% confidence interval, 36-70%). The 6-month overall survival was 79% (95% confidence interval, 61-89%). Twenty patients (61%) had at least a partial response. Outcome did not differ between the two treatment cohorts. Significant adverse events were infrequent and included a central nervous system hemorrhage in one patient, and one patient who developed thrombotic thrombocytopenic purpura.
conclusionBevacizumab and irinotecan is an active regimen with acceptable toxicity for patients with recurrent WHO grade 3 malignant glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.